ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08731
-0,20%
Bitcoin
66.191,95
-0,12%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Pharming Group NV (PHAR)

  7. Pharming Group NV (PHAR) News

PHAR

Pharming Group NV (PHAR)

Pharming Group NV
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:PHAR
DatumZeitQuelleÜberschriftSymbolFirma
15/05/202417h52Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHARPharming Group NV
08/05/202412h04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHARPharming Group NV
08/01/202415h17Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHARPharming Group NV
26/10/202315h25Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHARPharming Group NV
24/08/202308h00PR Newswire (US)Pharming Group to participate in September investor conferencesNASDAQ:PHARPharming Group NV
14/08/202307h00PR Newswire (US)Pharming Group to convene Extraordinary General Meeting of ShareholdersNASDAQ:PHARPharming Group NV
09/08/202307h00PR Newswire (US)Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in JapanNASDAQ:PHARPharming Group NV
09/08/202307h00PR Newswire (US)Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in JapanNASDAQ:PHARPharming Group NV
03/08/202317h09Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHARPharming Group NV
03/08/202307h00PR Newswire (US)Pharming Group reports second quarter and first half 2023 financial resultsNASDAQ:PHARPharming Group NV
18/07/202307h00PR Newswire (US)Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the BoardNASDAQ:PHARPharming Group NV
18/07/202307h00PR Newswire (US)Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the BoardNASDAQ:PHARPharming Group NV
13/07/202308h00PR Newswire (US)Pharming Group to report second quarter and first half 2023 financial results on August 3NASDAQ:PHARPharming Group NV
13/07/202308h00PR Newswire (US)Pharming Group to report second quarter and first half 2023 financial results on August 3NASDAQ:PHARPharming Group NV
01/06/202312h15Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:PHARPharming Group NV
01/06/202307h00PR Newswire (US)Pharming announces sale of priority review voucherNASDAQ:PHARPharming Group NV
01/06/202307h00PR Newswire (US)Pharming announces sale of priority review voucherNASDAQ:PHARPharming Group NV
25/05/202308h00PR Newswire (US)Pharming Group to attend the following Investor Conferences in JuneNASDAQ:PHARPharming Group NV
25/05/202308h00PR Newswire (US)Pharming Group to attend the following Investor Conferences in JuneNASDAQ:PHARPharming Group NV
17/05/202317h28PR Newswire (US)Pharming Group reports on results of the 2023 Annual General Meeting of ShareholdersNASDAQ:PHARPharming Group NV
11/05/202307h00PR Newswire (US)Pharming Group reports financial results for the first quarter of 2023NASDAQ:PHARPharming Group NV
11/05/202307h00PR Newswire (US)Pharming Group reports financial results for the first quarter of 2023NASDAQ:PHARPharming Group NV
26/04/202308h00PR Newswire (US)Pharming to attend the H.C. Wainwright BioConnect Investor Conference 2023NASDAQ:PHARPharming Group NV
19/04/202308h00PR Newswire (US)Pharming to attend the Van Lanschot Kempen Life Sciences Conference 2023NASDAQ:PHARPharming Group NV
19/04/202307h36PR Newswire (US)Notice of First Quarter 2023 ResultsNASDAQ:PHARPharming Group NV
13/04/202313h11PR Newswire (US)Pharming to present at the 22nd Annual Needham Virtual Healthcare Conference 2023NASDAQ:PHARPharming Group NV
11/04/202314h58Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:PHARPharming Group NV
11/04/202307h00PR Newswire (US)Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.NASDAQ:PHARPharming Group NV
11/04/202307h00PR Newswire (Canada)Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.NASDAQ:PHARPharming Group NV
11/04/202307h00PR Newswire (US)Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.NASDAQ:PHARPharming Group NV
 Showing the most relevant articles for your search:NASDAQ:PHAR

Kürzlich von Ihnen besucht

NYSE
RBS-R
COIN
HPCBTC
BIT
UC8K2V
Unicredit Bank
BIT
UC6M35
Unicredit Bank
COIN
BAYC20ETH
Bored Ape Yacht Club
COIN
OWCUST
ODUWA COIN
BIT
UC8YJX
Unicredit Bank
USOTC
BOREF
Borealis Exploration (PK)
USOTC
JGRRF
Jinchuan Group Internati... (PK)
BOV
SAPP34R
Sap
NYSE
NREF-A
NexPoint Real Estate Fin...
BIT
UC3F99
Unicredit Bank
COIN
CXPUSD
BIT
UC7ABR
Unicredit Bank
COIN
ECTEBTC
EurocoinToken
BIT
S5SCOI
Societe Generale Effekten
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten